IAVI and the International AIDS Society (IAS) released an advocacy brief outlining what can be gained through sustained investments in HIV vaccine research. From advancing the clinical pipeline, to conducting faster, smarter, and inclusive research, and strengthening regional vaccine research and manufacturing ecosystems, investments in HIV vaccine R&D represent a strategic opportunity to advance the HIV prevention field and broader vaccine development ecosystems.
Access the advocacy brief here.
Source : IAVI
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.